LM
Tulane University
An adjuvant that brings subunit immunogens up to the protection of conventional avian bronchitis vaccines.
Get the Discover digest
Receive a weekly email digest of the latest vaccine development solutions added by the network.Get the Discover digest
Receive a weekly email digest of the latest vaccine development solutions added by the network.Updated Sept 30, 2026
Vaccine development covers antigens, adjuvants, delivery formats and the manufacturing needed to make a dose repeatably. On Halo, the solutions cover poultry vaccines, companion animal and livestock vaccines, mucosal and vectored platforms, and delivery systems and adjuvants. Sign up to search the full network and post your specific need.
LM
Tulane University
An adjuvant that brings subunit immunogens up to the protection of conventional avian bronchitis vaccines.
Molecular Express, Inc.
A liposomal subunit vaccine against avian infectious bronchitis virus.
POP Biotechnologies
Liposome-displayed H5 antigen built with SNAP chemistry for highly pathogenic avian influenza.
Eureka Nanobioengineering
A modular poultry platform designed to be re-pointed quickly as IBV variants emerge.
DoriNano, Inc.
A DNA origami nanoparticle vaccine for avian bronchitis, thermostable by design.
Microparticle vaccines a poultry operation can give by spray, orally or in ovo.
A second-generation modified-live Leptospira vaccine for dogs, built with CRISPR-made deletions.
University of Crete
A personalized implantable vaccine on a laser-modified silicon scaffold, for feline virus.
Shanghai Veterinary Research Institute
A polyvalent live vector vaccine covering feline herpesvirus, calicivirus and panleukopenia.
Yangzhou University
Parainfluenza 5 and Sendai vectors expressing three feline antigens from one platform.
SP
Texas A&M University, College Station
A reproducible dry cow mastitis challenge model, so a vaccine candidate can be tested against real pathogens.
University of Virginia
Killed whole-cell genome-reduced bacteria used to display pathogen subunits.
WM
Kansas State University
An attenuated bovine parainfluenza vector giving mucosal and systemic protection against H5N1.
Sign up free to search the full network and post your specific need.
Already have an account?
Universities, startups, and suppliers with solutions in vaccine development.
Vaccine development organizationsResearchers and inventors advancing vaccine development.
Vaccine development expertsVaccine development on Halo is mostly veterinary. Poultry and companion animal programs outnumber human ones, and much of the platform work is about the route a dose takes and not the antigen it carries. On Halo it spans five groups, including poultry vaccines, companion animal and livestock vaccines, and mucosal and vectored platforms.
Stage of development. Work on vaccine development on Halo comes mostly from university programs. 87% are past proof of concept (TRL 4 or higher). Co-development and sponsored research are the usual partnering routes, and about 26% of the solutions that state terms offer pilot engagements.
Poultry first. Avian infectious bronchitis alone accounts for four different platforms, an adjuvanted subunit, a liposomal subunit, a DNA origami nanoparticle and a modular system meant to be re-pointed as variants emerge. Commercial pressure in poultry is pulling vaccine formats forward faster than human indications on the page.
The route as the product. Several solutions are about how a dose gets in and not what it contains: microparticles given by spray, orally or in ovo, a mucosal vector delivering both H5N1 and Ebola antigens, and one-step encapsulation for an adjuvant-free oral antigen. For a flock or a herd, the route decides whether a vaccine is usable at all.
Doses that survive the journey. Stabilization work sits beside the antigens. One platform stabilizes proteins, RNA and DNA broadly enough to cut cold chain cost; another manufactures nanocarriers continuously by jet mixing. Both treat distribution as part of the vaccine and not a problem for afterwards.
Vaccine development covers the antigens, adjuvants, delivery formats and manufacturing that turn an immune target into a dose that can be given repeatably. It spans viral vectors and subunit designs, lipid nanoparticles and other carriers, adjuvant chemistry, and the stabilization and fill processes that let a dose survive distribution. Human and veterinary vaccine developers do the work.
Four examples of vaccine development solutions on Halo include:
The most recently updated vaccine development solutions on Halo include:
There are 263 organizations with vaccine development solutions on Halo, 63 of them universities and research institutions. Among them are Tulane University, Molecular Express, Inc., and POP Biotechnologies. Most offer co-development or sponsored research. Sign up to see every organization working in the area and to send them your specific need.
Browsing vaccine development solutions on Halo is free. Sign up to search the full network and save the ones you want. Post your specific need to get exact matches. Organizations reply directly on the platform.
Over the past 12 months, R&D teams on Halo have posted these vaccine development needs:
Confirm digest type